KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant adverse impact on the shares. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) stock opened at $3.33 in last session, and closed at $3.33, while the day range of stock is $3.15 – $3.56. The stock showed a negative weekly performance of -38.22%.
LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, announced that it will release financial results for its second quarter ended December 31, 2013, after the market closes on Thursday, February 6, 2014. LifeVantage Corp (NASDAQ:LFVN) stock opened at $1.47, in last session and closed at $1.35, by losing -6.25%. The 52 week range of the stock is $1.35 – $2.76. Company’s market capitalization is $138.35 million.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) plan to end a Phase II study of the Tivozanib drug for treating breast cancer after not being able to enroll enough patients in the trial. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock decreased -5.65% and finished the last session at $1.67. The EPS of the stock remained -2.28. Company’s market capitalization is $86.61 million.
Evoke Pharma Inc (NASDAQ:EVOK) showed in a recent study that its nasal spray for the delivery of a generic gastrointestinal drug performed better than the traditional oral form. The nasal delivery method could help patients with diabetic gastroparesis take the drug when they are suffering from nausea and have difficulty swallowing a pill. Evoke Pharma Inc (NASDAQ:EVOK) stock opened the session at $10.85, and closed the session at $10.25. The 52 week range of the stock remained $6.75 – $14.25 and the day range was $10.17 – $11.10.
Leave a Reply